Core Viewpoint - Citigroup has initiated a 90-day positive catalyst observation for Kanglong Chemical, primarily driven by the upcoming announcement of last year's full-year performance and accelerated order growth, leading to a more optimistic guidance for this year [1] Group 1: Company Performance - The group is expected to become a leading indicator of customer demand recovery, providing clearer guidance for future revenue growth, which may result in this fiscal year's guidance exceeding market consensus and positively revaluing the stock price [1] Group 2: Investment Rating - Citigroup has assigned a "Buy" rating for Kanglong Chemical's H-shares with a target price of HKD 45, indicating confidence in the company's position as a global leader in drug research and development [1] Group 3: Industry Position - The company is capitalizing on the growth trend of the Chinese CRO industry while maintaining its leadership in drug research and development, and is also expanding into downstream late-stage clinical development and commercialization, as well as entering the biopharmaceutical sector [1]